Summary

Introduction Positron emission tomography (PET) with computed tomography (CT) using fluorine-18-labeled fluorodeoxyglucose (18F-FDG PET/CT) is a hybrid diagnostic method based on the cell's glucose uptake detection, which correlates with the degree of disease activity. While other diagnostic procedures fail to evaluate functional tissue, 18F-FDG PET/CT can be helpful in discovering active disease in patients with vascular graft infection.

Methods

This cohort retrospective study included 22 patients (17 male, five female; aged 61.7 ± 16.1) with suspected vascular graft infection. Blood analyses and CT were performed in all patients. Degree of glucose uptake was evaluated visually and semiquantitatively using maximal standardized uptake value (SUVmax). Findings were considered positive if focal fluoro-deoxyglucose (FDG) accumulation was greater in vascular graft projection than other parts of the blood vessel and liver.

Results

The signs of active disease were found in 19 patients (86%) (16 male, three female) at the level of implanted vascular grafts: six aortobifemoral (27%), four aortoiliac (18.2%), four of abdominal aorta (18.2%), two of thoracic aorta (9.1%), two femoral (9.1%), one femoropopliteal (4.5%) (SUVmax 7.9 ± 2.4). Two patients were considered true and one false negative—due to antibiotic usage, which reduces FDG uptake. PET/CT helped in treatment alteration of 12 patients, seven (31.8%) started new medicament therapy, five (22.7%) had a surgical graft replacement. Overall sensitivity of this method is 95%, specificity 100%, positive predictive value 100%, negative predictive value 66.6%, accuracy 95.4%.

Conclusion

18F-FDG PET/CT is a useful diagnostic method in detection of active vascular graft infection with high diagnostic accuracy, which is important in avoiding unnecessary surgery and appropriate therapy planning.

Keywords: 18F-FDG PET/CT; SUVmax; vascular graft; infection

Introduction

Cardiovascular disease is the leading cause of death worldwide [1]. Endovascular interventions rarely end up with infection, but in cases of infected prosthetic vascular graft, morbidity and mortality are high [2].

Infection and inflammation of cardiovascular system can be clinically presented by numerous nonspecific symptoms, which make them even more difficult to be recognized. Right diagnosis is made based on blood tests, hemoculture, ultrasound, and computed tomography (CT) [3, 4]. The most common causes of an infection are bacteria Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella and Enterococcus [5, 6]. Medicament treatment implies elimination of an infective agent by various antibiotics (Tetracycline, Methicillin, Penicillin), but the treatment of choice for graft infections is surgical removal and graft replacement [7, 8], which is why an accurate diagnosis is important to avoid unnecessary surgery.

Nowadays, positron emission tomography (PET) with CT using fluorine-18-labeled fluorodeoxyglucose (18F-FDG PET/CT) is used to assess the sights of an increased metabolism of glucose, such as in neoplastic cells, which is why PET/CT is mostly used in oncology [9, 10]. However, 18F-FDG PET/CT can identify the source of an infection or inflammation relying on its ability to recognize functional changes of the tissue, unlike radiologic modalities, which evaluate only morphology [11, 12]. Therefore, our aim was to evaluate the importance of 18F-FDG PET/CT in patients with suspected vascular graft infection, to detect the extent and degree of active disease.
METHODS

Patients

In this cohort retrospective study were included 22 patients (17 male and five female; aged 61.7 ± 16.1) with persistent systemic manifestations (fever, weakness, chills, muscle pain), who were referred to 18F-FDG PET/CT examination, to National PET Center of Clinical Center of Serbia, in the period between September 2012 to June 2018, to confirm vascular graft infection. Biochemical blood analyses, hemoculture and CT were performed in all patients. The criteria for inclusion in this study and indications for 18F-FDG PET/CT scan were as follows: suspicion of a recurrent cardiovascular infection based on positive hemoculture and blood analyses (elevated C-reactive protein, sedimentation) or fever of unknown origin in patients with positive medical history of graft implantation, as well as patients with follow up of at least six months. The criteria for exclusion were blood glucose level above 11 mmol/l, application of corticosteroid therapy, the existence of malignant disease and recent chemo/radiotherapy. All the patients gave their written consent to participate in the study which was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee.

Fluorine-18 labeled fluorodeoxyglucose examination

A 64-slice hybrid PET/CT (Biograph, TruePoint64, Siemens Medical Solutions, Inc. USA) was used for scanning, which was initiated one hour after intravenous injection of 18F-FDG. Imaging was performed from the base of the skull to the mid tights, by non-contrast-enhanced low dose CT and PET. CT, PET, and fused PET/CT images were then demonstrated for interpretation on the workstation. Level of metabolic activity was analyzed visually and semiquantitatively using the maximal standardized uptake value (SUVmax), which was calculated according to the patient's weight and admitted radioactivity. 18F-FDG PET/CT findings were found to be positive in cases of focal glucose uptake that is higher in a projection of implanted vascular graft than the accumulation in other parts of the blood vessel and liver.

Findings of 18F-FDG PET/CT examination were compared to the bacterial culture results of an infected vascular graft from surgery, and results of clinical follow-up of at least six months.

Statistical analyses

The results were showed as mean ± standard deviation (SD). The 18F-FDG PET/CT and CT diagnostic values were calculated by specificity, sensitivity, positive predictive value, negative predictive value and accuracy.

RESULTS

The sights of pathological 18F-FDG uptake were found in 19 out of 22 patients (86.4%) (16 male and three female), which were considered true positive. Increased glucose metabolism was showed in a projection of implanted vascular grafts: six aortobifemoral (27%), four aortoiliac (18.2%), four of abdominal aorta (18.2%) (Figure 1), two of thoracic aorta (9.1%), two femoral (9.1%) and 1 femoropopliteal (4.5%) (Figure 2). Mean SUVmax values of an active disease were 7.9 + 2.4 (Table 1). Out of 19 true positive patients, 13 (68.4%) had manifested symptoms such as fever, swelling, weakness and pain of an affected limb and 11 (57.9%) had leukocytosis and elevated C-reactive protein.

Out of three negative patients, two were considered true negative and one was false negative – due to antibiotic usage in a period of examination, which reduces 18F-FDG uptake. 18F-FDG PET/CT helped in treatment alteration of 12 patients, seven (31.8%) started a new medicament therapy (antibiotic) and five (22.7%) had a surgical graft replacement during which an infective agent was proved (Staphylococcus species), while seven patients remained on the same therapy as the disease was still active on PET/CT (Table 2).

Four patients (three men and one woman) had a control 18F-FDG PET/CT in order to evaluate therapy response. Recurrent disease was found in one patient after the antibiotic interruption.

CT failed to detect graft infection in 14 patients (63.3%). In eight patients the results correlated to 18F-FDG PET/CT, five were true positive and three were true negative. Calculated sensitivity of CT is very low (26.3%), with higher specificity (66.7%). However, overall sensitivity of 18F-FDG PET/CT is 95%, specificity 100%, positive predictive value 100%, negative predictive value 66.6%, accuracy 95.4.
DISCUSSION

Mortality of vascular graft infection has high rates, which is why the appropriate diagnosis is a priority, especially when infection is asymptomatic. Because of the high glucose uptake of inflammatory cells, $^{18}$F-FDG PET/CT is an appropriate tool to use in detecting suspected inflammation and infection [13].

Diagnostic tool of choice in a progressive vascular graft infection is CT; however, the frequency of false negative results is relatively high, which is why $^{18}$F-FDG PET/CT was introduced as an alternative modality for infectious lesions [14]. In our study, 63.6% of findings were false negative on CT, in comparison to one false negative on $^{18}$F-FDG PET/CT. This can be explained by the fact that both sensitivity and specificity of CT decrease in chronic infection [4, 15]. False-negative finding in one patient was a result of antibiotic therapy used in a period of PET/CT examination. In the study of Guenther et al. [16], one patient was also considered false negative for the same reason. Antibiotics reduce inflammation and accumulation of radiopharmaceutical, which can undermine the diagnostic accuracy. In addition, subacute and low-grade infections may also be problematic to interpret, which is why it is important to take all into account – clinical, biochemical and diagnostic findings in the final conclusion [17].

False-negative finding in one patient was a result of antibiotic therapy used in a period of PET/CT examination. In the study of Guenther et al. [16], one patient was also considered false negative for the same reason. Antibiotics reduce inflammation and accumulation of radiopharmaceutical, which can undermine the diagnostic accuracy. In addition, subacute and low-grade infections may also be problematic to interpret, which is why it is important to take all into account – clinical, biochemical and diagnostic findings in the final conclusion [17].

The results of our study show high sensitivity (95%) and specificity (100%) of $^{18}$F-FDG PET/CT in detection of vascular graft infection, similar to those in the paper of Keidar et al. [18], who reported sensitivity of 93% and specificity of 91%, as well in other papers [19, 20]. However, specificity may vary, which can be explained by physiological uptake in postoperative inflammation, healing tissue or chronic inflammatory reactions induced by the graft [15, 16, 21]. $^{18}$F-FDG PET/CT had better diagnostic performance than CT in this study, similar to the results of other studies [4, 22].

One of this study’s exclusion criteria was high glucose level, over 11 mmol/L. However, a study by Rabkin et al. [23], proved that hyperglycemia might reduce the sensitivity of $^{18}$F-FDG PET/CT but in cases of malignancy, while in those with infection/inflammation no meaningful impact on the false negative results was found.

Symptoms and elevation of inflammatory parameters do not have to be presented in all of the patients with an infected vascular graft. In this study, out of 86.4% positive patients on $^{18}$F-FDG PET/CT, 57.9% had leukocytosis and elevated C-reactive protein. In a study by Wassélius et al. [24], was reported normal CRP, or discretely elevated, in 13 out of 15 patients and vascular graft infection was confirmed in only one patient.

In our study, $^{18}$F-FDG PET/CT helped in treatment alteration of 63.2% of the patients, which is why it is considered to be a helpful tool in avoiding unnecessary surgery and it contributes to the optimal treatment [15, 25].

CONCLUSION

According to our results, $^{18}$F-FDG PET/CT is a useful diagnostic method in the detection of active vascular graft infection with high diagnostic accuracy. Because of its ability to
evaluate morphology and functional tissue using SUVmax, \(^{18}\text{F}-\text{FDG PET/CT}\) gives an objective assessment of sights and level of the disease activity, which is why it is proved to be superior to CT. It contributes to avoiding unnecessary surgery, appropriate therapy planning and in the assessment of therapy effectiveness. However, \(^{18}\text{F}-\text{FDG PET/CT}\) had a limited role in the detection of active vascular graft infection in the patient treated with antibiotics.

**Conflict of interest:** None declared.

**REFERENCES**

1. Pashneh-Tala S, MacNeil S, Claeyssens F. The Tissue-Engineered Vascular Graft-Past, Present, and Future. Tissue Eng Part B Rev. 2015; 21(1):168–100.
2. Hasse B, Husmann L, Zinkernagel A, Weber R, Lachat M, Mayer D. Vascular graft infections. Swiss Med Wkly. 2013; 143:w13754.
3. Kilic A, Armasuutakis DJ, Reifsnyder T, Black JH, Abularrage CJ, Perler BA, et al. Management of infected vascular grafts. Vasc Med. 2016; 21(1):53–60.
4. Legout L, D’Elia PV, Sarraz-Bournet B, Haulon S, Meybeck A, Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT: Utility and Applications in Clinical Oncology. Clin Med Oncol. 2011; 5(2):16–9.
5. Varino Sousa J, Antunes L, Mendes C, Marinho A, Gonçalves O, Gonçalves A, et al. Prosthetic vascular graft infections: A center experience. Angiologia e Cirurgia Vascular. 2014; 10(2):52–7.
6. Russu E, Muresun A, Grigorescu B. Vascular graft infection management. Manag Health. 2011; 15(3):16–9.
7. Szilagyi DE, Smith RF, Elliott JP, Vrandecic MP. Infection in arterial reconstruction with synthetic grafts. Ann Surg. 1972; 176(3):321–33.
8. Erb S, Sidler JA, Elzi L, Gurke L, Battegay M, Widmer AF, et al. Surgical and Antimicrobial Treatment of Prosthetic Vascular Graft Infections at Different Surgical Sites: A Retrospective Study of Treatment Outcomes. PloS One. 2014; 9(11):e112947.
9. Almuhaidib A, Papatheasiiou N, Bomanji J. \(^{18}\text{F}-\text{FDG PET/CT}\) imaging in oncology. Ann Saudi Med. 2011; 31(1):3–13.
10. Pinilla I, Rodriguez-Vigil B, Gómez-León N. Integrated \(^{18}\text{F}-\text{FDG PET/CT}\): Utility and Applications in Clinical Oncology. Clin Med Oncol. 2008; 2:118–98.
11. Lebeck AM, Gaardsting A, Lovf A, Graff J, Markova E, Bertelsen AK, et al. Whole-Body \(^{18}\text{F}-\text{FDG PET/CT}\) Is Superior to CT as First-Line Diagnostic Imaging in Patients Referral with Serious Nonspecific Symptoms or Signs of Cancer: A Randomized Prospective Study of 200 Patients. J Nucl Med. 2017; 58(7):1058–64.
12. Vaidyanathan S, Patel CN, Scarsbrooks AF, Chowdhury FU. FDG PET/CT in infection and inflammation—current and emerging clinical applications. Clin Radiol. 2015; 70(4):787–800.
13. Städler P, Bílohlávek O, Spacek M, Michálek P. Diagnosis of vascular prosthesis infection with FDG-PET/CT. J Vasc Surg. 2004; 40(6):1246–7.
14. Saleem BR, Pol RA, Slart RH, Reijnen MM, Zeebregts CJ. \(^{18}\text{F}-\text{Fluorodeoxyglucose positron emission tomography/CT}\) scanning in diagnosing vascular prosthetic graft infection. Biomed Res Int. 2014; 2014:471971.
15. Tayama E, Horii H, Ueda T, Kono T, Imasaka K, Harada T, et al. Usefulness of \(^{18}\text{F}-\text{FDG PET/CT}\) in aortic graft infection: two cases. J Cardiothorac Surg. 2014; 9:4.
16. Guenther SP, Cyran CC, Rominger A, Saam T, Kazmierczak PM, Bagaev E, et al. The relevance of \(^{18}\text{F}-\text{fluorodeoxyglucose positron emission tomography/computed tomography imaging}\) in diagnosing prosthetic graft infections post cardiac and proximal thoracic aortic surgery. Interact Cardiovasc Thorac Surg. 2015; 21(4):450–8.
17. Tecleg G, Sørensen J, Björck M, Savitcheva I, Wanhainen A. Detection of aortic graft infection by \(^{18}\text{F}-\text{fluorodeoxyglucose positron emission tomography combined with computed tomography}\). J Vasc Surg. 2007; 45(4):828–30.
18. Keidar Z, Engel A, Hoffman A, Israel O, Nitecki S. Prosthetic vascular graft infection: the role of \(^{18}\text{F}-\text{FDG PET/CT}\). J Nucl Med. 2007; 48(8):1230–6.
19. Sah BR, Husmann L, Mayer D, Scherrer A, Rancic Z, Puipe G, et al. Diagnostic performance of \(^{18}\text{F}-\text{FDG PET/CT}\) in vascular graft infections. Eur J Vasc Endovasc Surg. 2015; 49(4):455–64.
20. Šaponjski J, Šobić-Šaranović D, Odalović S, Stojilkovikj M, Pantović J, Petrović N, et al. The detection of endocarditis, post implantation grafts, arteritis and other related disorders by \(^{18}\text{F}-\text{FDG PET/CT}\). Hell J Nucl Med. 2017; 20 Suppl37–44.
21. Keidar Z, Nitecki S. FDG-PET for the detection of infected vascular grafts. Q J Nucl Med Mol Imaging. 2009; 53(1):35–40.
22. Bruggink JLM, Glaudemans AWJM, Saleem BR, Meerwaldt R, Alkefaji H, Prins TR, et al. Accuracy of FDG-PETeCT in the Diagnostic Work-up of Vascular Prosthetic Graft Infection. Eur J Vasc Endovasc Surg. 2010; 40(3):348–54.
23. Rabbik Z, Israel O, Keidar Z. Do hyperglycemia and diabetes affect the incidence of false-negative \(^{18}\text{F}-\text{FDG PET/CT}\) studies in patients evaluated for infection or inflammation and cancer? A Comparative analysis. J Nucl Med. 2010; 51(7):1015–20.
24. Wassell R, Malmstedt J, Kalin B, Larsson S, Sundin A, Hedin E, et al. High \(^{18}\text{F}-\text{FDG Uptake in synthetic aortic vascular grafts on PET/CT}\) in symptomatic and asymptomatic patients. J Nucl Med. 2008; 49(10):1601–5.
25. Shahani L. Vascular graft infections and role of PET/CT in patients with persistent bacteraemia. BMJ Case Rep. 2015; 2015.
САЖЕТАК
Увод Позитронска емисиона томографија (ПЕТ) са компјутеризованом томографијом (КТ) уз коришћење флуор-18-обележене флуордеоксиглукозе (18Ф-ФДГ ПЕТ/КТ) јесте хибридна дијагностичка метода базирана на детекцији ћелијског накупљања глукозе, који корелира са степеном активности болести. Док друге дијагностичке методе немају могућност процене функције ткива, 18Ф-ФДГ ПЕТ/КТ може бити од велике помоћи у откривању активне болести код болесника са инфекцијом васкуларног графта.

Методе У овој кохортној ретроспективној студији је било укључено 22 болесника (17 мушкараца, пет жена; година старости 61,7 ± 16,1) са суспектном инфекцијом васкуларног графта. Анализа крви и КТ су урађени свим болесникима. Степен преузимања глукозе је процењен визуелно и семиквантитативно коришћењем максималне стандардизоване вредности уноса (МСВ max.). Налази су сматрани позитивним уколико је фокално појачано накупљање ФДГ било интензивније у нивоу васкуларног графта него у другим деловима крвног суда и јетри.

Резултати Активна болест је уочена код 19 болесника (86%) у нивоу уgraђеног васкуларног графта (16 мушкараца, три жене): шест аортобифеморалних (27%), четири аортоилијачна (18,2%), четири абдоминална (18,2%) и два са торакалном аортом (9,1%), два феморална (9,1%) и један феморопоплитеални (4,5%) (МСВ max. 7,9 ± 2,4). Два болесника су сматрана стварно и један лажно негативним – услед коришћења антибиотика који смањују накупљање ФДГ. ПЕТ/КТ је допринела даљем лечењу 12 болесника. Код њих седам (31,8%) започета је медикаментна терапија, а код пет (22,7%) хируршка замена графта. Свеукупна сензитивност ове методе је 95%, специфичност 100%, позитивна предиктивна вредност 100%, негативна предиктивна вредност 66,6%, тачност 95,4%.

Закључак 18Ф-ФДГ ПЕТ/КТ је корисна метода у детекцији инфекције васкуларног графта са високим дијагностичким тачношћу, што је битно за избегавање непотребних операција и планирање одговарајуће терапије.

Кључне речи: 18Ф-ФДГ ПЕТ/КТ; МСВ max.; васкуларни графт; инфекција